-
公开(公告)号：US20190077869A1
公开(公告)日：2019-03-14
申请号：US16118994
申请日：2018-08-31
发明人： Walter Fiedler , Jasmin Wellbrock , Hauke Stamm , Felix Klingler
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395 , C07K14/725 , C07K16/18 , A61K39/00
摘要： The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.
-
2.发明申请IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS 审中-公开用于治疗血液肿瘤的免疫检查点抑制剂公开(公告)号：US20170037133A1
公开(公告)日：2017-02-09
申请号：US15229438
申请日：2016-08-05
发明人： Walter Fiedler , Jasmin Wellbrock , Hauke Stamm , Felix Klingler
IPC分类号： C07K16/28 , C07K14/725 , A61K39/00 , A61K45/06 , C07K16/18 , A61K39/395
CPC分类号： C07K16/2851 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , C07K14/7051 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K16/2896 , C07K2317/31 , C07K2317/62 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/74 , Y02A50/466
摘要： The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.
摘要翻译： 本发明提供了用于治疗血源性癌症，特别是急性髓细胞的方法中用于CD112（Nectin-2，PVRL2），CD155（PVR），Galectin-9，TIM-3和/或TIGIT的抑制剂 白血病（AML）。 此外，本发明提供了包含抑制CD112（Nectin-2，PVRL2），CD155（PVR），Galectin-9，TIM-3和/或TIGIT和CART细胞的抑制剂的药物组合物。 本发明还提供了包含抗CD112（Nectin-2，PVRL2），CD155（PVR），Galectin-9，TIM-3和/或TIGIT的抑制剂和能够与T细胞接合的抗体构建体的药物组合物。
-
搜索结果
2 条记录 (耗时 0.013 秒)
